Vivimed Labs Limited · NSE:VIVIMEDLAB
Vivimed Labs — Q1 FY2014 Earnings Presentation
18 slides from Vivimed Labs's earnings presentation, Aug 13, 2013
Slide 1: Q1 FY 2014 Earnings Presentation
Vivimed Labs Limited Q1 FY 2014 Earnings Presentation August 13, 2013 1 www.vivimedlabs.com © Vivimed Labs Ltd 2010 All rights reserved
Slide 2: Disclaimer
Disclaimer No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the d
Slide 3: Where Chemistry and Quality Matters
Where Chemistry and Quality Matters Unique Business Model Best-in-Class Operations • Uses chemistry to create ingredients which • 12 manufacturing facilities and 5 R&D touch human life on a daily basis centers across the world • Focused on the Health Care, Personal Care, • 4 US FDA approved sites Ho
Slide 4: Business Segments
Business Segments Healthcare Personal Care Home Care Industrials 71% of Q1 FY14 sales 17% of Q1 FY14 sales 9% of Q1 FY14 sales 3% of Q1 FY14 sales • Active • Sun Care • Antimicrobials • Photo Chromic Pharmaceutical • Skin Care • Specialty Dyes Ingredients (API) • Hair Care Intermediates • Imaging Ch
Slide 5: Consolidated Financial Performance
Consolidated Financial Performance Performance Highlights Q1 FY2014 Revenue Breakup 2.6% Net Sales of Rs. 3,439 million 9.3% 71.4% 16.7% o Increased 16.1% q-o-q and 25.4% y-o-y EBITDA of Rs. 488 million and margins of 14.2% o Increased 8.0% q-o-q Net Profit of Rs. 200 million and margins of 5.
Slide 6: Financial Performance
Financial Performance Consolidated Financials Q1 y-o-y Q4 q-o-q (Rs. million) FY2014 FY2013 Growth (%) FY2013 Growth (%) Net Sales 3,439 2,743 25.4% 2,961 16.1% EBITDA 488 619 (21.2)% 452 8.0% Margin (%) 14.2% 22.6% 15.3% Net Profit 200 261 (23.5)% 150 33.3% Margin (%) 5.8% 9.5% 5.1% Basic EPS (Rs.)
Slide 7: Segment Highlights
Segment Highlights Healthcare Segment Q1 FY14 Revenue: Rs. 2,458 mn • Revenue growth driven by the API business – ramp up of a key CMO account and better client penetration 3.4% 15.7% • Process improvements, new product development and efficient procurement to remain key focus areas for enhancing se
Slide 8: Segment Highlights
Segment Highlights Home Care Segment Q1 FY14 Revenue: Rs. 320 mn • Cross selling efforts across existing customer in multiple 0.4% geographies resulting in growth for Antimicrobial segment • Specialty intermediates growth trajectory remains stable 45.3% 54.3% Antimicrobials Speciality intermediates
Slide 9: Acquisition of APMPL SOD
Acquisition of APMPL SOD Recent acquisition of a US FDA approved FDF facility will provide immediate access to the regulated markets Immediate Access to the Regulated Markets • US FDA approved facility with 1.2 billion SOD per annum manufacturing capacity • Immediate access to regulated market such
Slide 10: Quarterly Financial Trends
Quarterly Financial Trends Net Sales Key Observations 3,439 • Q1 FY14 sales driven by strong traction in the API business and consistent growth trend in the 2,961 2,743 2,758 2,744 Specialty Chemicals business Rs. Million • Q4 FY13 Healthcare segment grew by 24.2% on q-o-q basis and 14.7% y-o-y basi
Slide 11: Quarterly Financial Trends
Quarterly Financial Trends Net Profit and Margin Key Observations • Q1 FY14, Net profit increased by 33.3% 261 255 sequentially 200 • Finance costs have stabilized after the one-off Rs. Million 9.5% 9.3% 169 150 reduction seen in Q4 FY2013 6.2% 5.8% • Net Profit margins improved sequentially as tax
Slide 12: Capital Markets
Capital Markets Shareholding Structure Key Institutional Investors 30.3% 39.8% 2.5% 27.4% Promoters FII DII Others Shareholding Pattern Trend Shareholders Sep-12 Dec-12 Mar-13 Jun-13 Promoters1 45.2% 45.2% 39.7% 39.8% FII / FDI 17.2% 16.4% 27.5% 27.4% DII 0.4% 0.3% 0.3% 2.5% Others 37.2% 38.1% 32.5%
Slide 13: Strategic Direction
Strategic Direction Continue to strengthen engagements with marquee customer base through superior product development and delivery capabilities Where Chemistry and Quality Matters Move up the value chain through vertical integration in Healthcare (R&D to manufacturing of API / FDF / brands) and tar
Slide 14: Global Reach
Global Reach A multinational global platform that provides Vivimed access to markets and significant cost advantage Kashipur, Uttarakhand Haridwar, Uttarakhand Sant Celoni, Spain Lliçà de Vall, Spain Kolkata Cuernavaca, Mexico Bonthapally, Hyderabad Bidar, Karnataka Bolarum, Hyderabad Jeedimetla, Hy
Slide 15: Strong Transnational Management Team
Strong Transnational Management Team Name & Designation Profile Santosh Varalwar • First generation entrepreneur MD & CEO • Evolves the business strategy and guides the implementation • Indentifying potential business opportunities and exercising the choices • Setting the growth path for the Company
Slide 16: Annexure – Quarterly Consolidated P&L Statement
Annexure – Quarterly Consolidated P&L Statement Profit & Loss Statement (Rs. million) Q1 FY13 Q2 FY13 Q3 FY13 Q4 FY13 Q1 FY14 Revenues Net Sales / Income from Operations (Net of Excise Duty) 2,725 2,661 2,721 2,981 3,408 Other Operating Income 18 97 23 (19) 32 Total Revenues 2,743 2,758 2,744 2,961
Slide 17: Annexure – Segment Highlights
Annexure – Segment Highlights Consolidated Performance Q1 y-o-y Q4 q-o-q (Rs. million) FY2014 FY2013 Growth (%) FY2013 Growth (%) Segment Revenue 3,408 2,725 25.0% 2,981 14.3% Specialty chemicals 983 883 11.4% 1,029 (4.4)% Healthcare 2,424 1,842 31.6% 1,952 24.2% EBIT 342 478 (28.5)% 289 18.3% Margi
Slide 18: Thank You
Thank You Contact Details: Vivimed Labs Limited Veernag Towers, Habsiguda, Hyderabad 500 007 www.vivimedlabs.com Priyanka Mukherjee +91 40 2717 6005 Vivimed Labs Limited Priyanka.Mukherjee@vivimedlabs.com Saket Somani +91 22 3953 7444 Churchgate Partners saket@churchgatepartnersindia.com